Search Patents
  • SARS-CoV-2 mRNA Vaccine and Preparation Method and Use Thereof
    Publication number: 20240075126
    Abstract: Provided is a SARS-CoV-2 mRNA vaccine, and the preparation method and use thereof. The present invention provides an mRNA molecule capable of encoding a target polypeptide, wherein the target polypeptide comprises an NTD-RBD natural domain in the Spike (S) protein of SARS-CoV-2, and wherein the NTD-RBD natural domain comprises an NTD fragment and an RBD fragment, the NTD fragment and the RBD fragment being linked together via a natural amino acid sequence derived from the S protein as a linker. The present invention provides an mRNA encoding a NTD-RBD natural domain in the Spike protein of SARS-CoV-2, which achieves an immune effect against SARS-CoV-2 mutant strains and is widely applicable.
    Type: Application
    Filed: April 29, 2022
    Publication date: March 7, 2024
    Inventor: Yong HU
  • APTAMERS AGAINST SARS-COV-2
    Publication number: 20230228751
    Abstract: The invention relates to one or more aptamers isolated against the SARS-CoV-2 spike protein and methods of using the same. Certain embodiments of the invention relate to methods of detecting the presence, absence or amount of SARS-CoV-2 in a sample using the one or more aptamers described herein. In certain embodiments, the invention relates to one or more aptamers that are capable of specifically binding to SARS-CoV-2 proteins, including aptamers that are capable of specifically binding to the S1 subunit (including the receptor binding domain (RBD)) and/or the S2 subunit within their native conformation as part of the SARS-CoV-2 spike protein in its trimeric form or as separate monomers.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Arron TOLLEY, David BUNKA, Edward BARNES, Banushan BALANSETHUPATHY, Harriet FLYNN, Janice ROBOTTOM, Laura MILBURN, Phoebe O'HARA, Joe REED
  • EXPRESSION OF PEDV SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME
    Publication number: 20200080101
    Abstract: A plant produced vaccine for Porcine Epidemic Diarrhea Virus (PEDV) is provided where the Spike protein of the virus is expressed in a plant by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleoic acid encoding the Spike protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. The plant expresses the S1 polypeptide at levels of at least 10 mg/kg of seed of said plant. When orally administered to an animal, a protective response is observed including a serum antibody response.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 12, 2020
    Inventors: John Howard, Erin Egelkrout, Celine Hayden
  • MODIFIED POLYPEPTIDES WITH IMPROVED PROPERTIES
    Publication number: 20240033343
    Abstract: This disclosure relates generally to modified SARS-CoV-2 spike polypeptides. More particularly, the present disclosure relates to modified SARS-CoV-2 spike proteins with improved properties, to chimeric polypeptides comprising these modified proteins, and to complexes comprising the chimeric polypeptides. The present disclosure also relates to the use of these modified polypeptides, chimeric polypeptides and complexes in compositions and methods for eliciting an immune response to ACE2-interacting coronaviruses, including SARS-CoV-2, and/or for treating or inhibiting the development of ACE2-interacting coronaviruses infections.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 1, 2024
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: Keith CHAPPELL, Paul YOUNG, Daniel WATTERSON
  • SARS-CoV-2 mRNA vaccine and preparation method and use thereof
    Patent number: 11931410
    Abstract: Provided is a SARS-CoV-2 mRNA vaccine, and the preparation method and use thereof. The present invention provides an mRNA molecule capable of encoding a target polypeptide, wherein the target polypeptide comprises an NTD-RBD natural domain in the Spike (S) protein of SARS-CoV-2, and wherein the NTD-RBD natural domain comprises an NTD fragment and an RBD fragment, the NTD fragment and the RBD fragment being linked together via a natural amino acid sequence derived from the S protein as a linker. The present invention provides an mRNA encoding a NTD-RBD natural domain in the Spike protein of SARS-CoV-2, which achieves an immune effect against SARS-CoV-2 mutant strains and is widely applicable.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 19, 2024
    Assignee: SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD.
    Inventor: Yong Hu
  • Systemic delivery of non-viral vector expressing SARS viral genomic vaccine
    Publication number: 20050025788
    Abstract: The present invention relates to a non-viral vector for SARS Viral Genomic Vaccine. The present invention also relates to a non-targeted lipoplex or PEGylated lipoplex formulation for accumulating SARS spike genome in the lung to that results in expression of SARS spike protein.
    Type: Application
    Filed: June 4, 2004
    Publication date: February 3, 2005
    Inventor: George Chou
  • Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
    Patent number: 11740240
    Abstract: The present invention relates to the development of novel immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples. Novel multiplex and singleplex immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples are also provided.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: August 29, 2023
    Assignee: BIO-RAD LABORATORIES, INC.
    Inventors: Qian Gao, Ravi Kaul, Shuxia Zhou, Roger P. Walker
  • NOVEL IMMUNOGENIC CORONAVIRUS PEPTIDES AND COMPOSITIONS THEREOF
    Publication number: 20230310587
    Abstract: This application relates to isolated proteins comprising an amino acid sequence which comprises at least 2 mutations relative to a SARS-CoV-2 Spike protein template sequence, isolated nucleic acid encoding said proteins, and vaccine compositions comprising said proteins.
    Type: Application
    Filed: January 27, 2023
    Publication date: October 5, 2023
    Inventors: Michiel Niesen, Venkataramanan Soundararajan, Rohit Suratekar, Pritha Ghosh, Karthik Murugadoss, Greg Donadio, Aiveliagaram Venkatakrishnan
  • SARS-COV-2 ANTIBODIES AND USES THEREOF
    Publication number: 20230391856
    Abstract: Provided herein are antibodies that bind to SARS-CoV-2 spike protein or a fragment thereof (e.g., receptor binding domain (RBD)), host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to SARS-CoV-2 spike protein or a fragment thereof (e.g., receptor binding domain) and methods of using such antibodies to diagnose, prevent or treat a SARS-CoV-2 infection, or COVID-19.
    Type: Application
    Filed: October 22, 2021
    Publication date: December 7, 2023
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Thomas Moran, Thomas Kraus, Domenico Tortorella, J. Andrew Duty
  • Expression of PEDV sequences in plants and plant produced vaccine for same
    Patent number: 11566255
    Abstract: A plant produced vaccine for Porcine Epidemic Diarrhea Virus (PEDV) is provided where the Spike protein of the virus is expressed in a plant by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleoic acid encoding the Spike protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. The plant expresses the S1 polypeptide at levels of at least 10 mg/kg of seed of said plant. When orally administered to an animal, a protective response is observed including a serum antibody response.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: January 31, 2023
    Assignee: MAZEN ANIMAL HEALTH INC.
    Inventors: John Howard, Erin Egelkrout, Celine Hayden
  • Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines
    Publication number: 20210139543
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Application
    Filed: November 3, 2020
    Publication date: May 13, 2021
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines
    Publication number: 20200407402
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Application
    Filed: September 14, 2020
    Publication date: December 31, 2020
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • STABILIZED CORONAVIRUS SPIKE (S) PROTEIN IMMUNOGENS AND RELATED VACCINES
    Publication number: 20240140993
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Application
    Filed: November 7, 2023
    Publication date: May 2, 2024
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • Stabilized coronavirus spike (S) protein immunogens and related vaccines
    Patent number: 10906944
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: February 2, 2021
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • Stabilized coronavirus spike (S) protein immunogens and related vaccines
    Patent number: 11845777
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: December 19, 2023
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXES
    Publication number: 20230338511
    Abstract: Recombinant protein coronavirus antigens and vaccine compositions using the same, include a recombinant protein that is a single-chain (SC) viral membrane protein complex derived from the spike (S), envelop (E) and membrane (M) protein of a coronaviruses such as SARS-CoV-2, the causal agent for COVID-19. Methods for immunization of a subject using the vaccine compositions treats or prevents clinical signs caused by coronaviruses infection.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 26, 2023
    Inventors: Ke-He Ruan, Xinli Liu, Renzhong Lu
  • MODIFIED ALPHAVIRUS FOR USE AS COVID-19 VACCINE
    Publication number: 20230218745
    Abstract: Modified alphaviruses encoding a SARS-CoV-2 spike protein or antigenic segment of the SARS-CoV-2 spike protein are provided. The modified alphaviruses include replicative defective Sindbis viruses. The modified viruses express or are administered with an immunomodulatory agent that is an agonist antibody or antigenbinding fragment thereof, or a cytokine, or a combination thereof. Pharmaceutical compositions that include the modified alphaviruses and methods of using the modified alphaviruses and compositions that contain them are provided. The compositions are used to stimulate a therapeutic or protective effect against SARS-CoV-2 infection that includes humoral and cell mediated responses.
    Type: Application
    Filed: May 28, 2021
    Publication date: July 13, 2023
    Inventors: Daniel MERUELO, Silvana OPP, Antonella SCAGLIONE, Christine PAMPENO, Alicia Hurtado MARTINEZ, Ziyan LIN
  • Lateral Flow Device for Detecting SARS-CoV-2 Antibodies in Human and Animal Samples
    Publication number: 20220050102
    Abstract: The invention provides a lateral flow device and methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a sample of bodily fluid of an animal or human. The test methods include contacting the sample with a conjugate comprising a recombinant SARS-CoV-2 spike protein antigen that has been conjugated to a detection agent, wherein an antigen-antibody complex is formed between the SARS-CoV-2 spike protein antigen conjugate and SARS-CoV-2 antibodies present in the sample; capturing the formed antigen-antibody complex with an Fc-binding molecule; and detecting the captured complex.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 17, 2022
    Inventors: Joshua T. Lizer, Jason J. Workman, James P. Gillies, Eric T. Baima, Rajesh K. Mehra
  • METHODS AND COMPOSITIONS FOR TREATING INFECTIONS
    Publication number: 20220233683
    Abstract: The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 28, 2022
    Inventor: Barbara L. Hibner
  • COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION
    Publication number: 20240059741
    Abstract: The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).
    Type: Application
    Filed: December 24, 2021
    Publication date: February 22, 2024
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hyun Goo WOO, Masaud SHAH, Sung Ung MOON
Narrow Results

Filter by US Classification